Practice guidelines do not advise that platinum agents should be used for most patients with early stage, HER2-negative breast cancer (8); thus, we were surprised to find twofold greater odds of platinum receipt by BRCA1/2 PV carriers vs noncarriers with HR-positive, HER2-negative disease. Here, ERBB2 is linked to breast cancer.